Marty M - Search Results

1

[Oxaliplatin: perspectives and future developments].

Marty M, Cottu PH, Lerebours F, Bedairia N, Hocini H, Espié M. Marty M, et al. Bull Cancer. 2001 Aug;88 Spec No:S5-8. Bull Cancer. 2001. PMID: 11567907 French. No abstract available.

2

[Clinical activity spectrum of irinotecan].

Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. Cottu PH, et al. Among authors: marty m. Bull Cancer. 1998 Dec;Spec No:21-5. Bull Cancer. 1998. PMID: 9932080 Free article. Review. French.

3

[Anti-epidermal growth factor receptor treatment: a new paradigm for conducting therapeutic trials].

Marty M, Bedairia N, Armand JP. Marty M, et al. Bull Cancer. 2003 Nov;90 Spec No:S245-50. Bull Cancer. 2003. PMID: 14763147 Free article. French.

4

[Individualized anticancer therapies: which regulatory guidelines?].

Bedairia N, Marty M. Bedairia N, et al. Among authors: marty m. Bull Cancer. 2008 Oct;95(10):985-8. doi: 10.1684/bdc.2008.0733. Bull Cancer. 2008. PMID: 19004730 Review. French.

5

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study.

Cottu PH, Extra JM, Espie M, Marolleau JP, de Roquancourt A, Makke J, Miclea JM, Laurence V, Mayeur D, Lerebours F, Cuvier C, Marty M. Cottu PH, et al. Among authors: marty m. Br J Cancer. 2001 Nov 2;85(9):1240-6. doi: 10.1054/bjoc.2001.2069. Br J Cancer. 2001. PMID: 11720455 Free PMC article. Clinical Trial.

6

[Promising results of bimonthly chemotherapy with high dose cyclophosphamide and epirubicin in induction treatment of inflammatory cancer of the breast].

Culine S, Extra JM, Espie M, Bourstyn E, Dieras V, Giacchetti S, Maylin C, De Rocquancourt A, Morvan F, Marty M. Culine S, et al. Among authors: marty m. Bull Cancer. 1993 Nov;80(11):994-1000. Bull Cancer. 1993. PMID: 8081037 French.

7

Optimizing chemotherapy for patients with advanced breast cancer.

Marty M, Espie M, Cottu PH, Cuvier C, Lerebours F. Marty M, et al. Oncology. 1999 Jul;57 Suppl 1:21-6. doi: 10.1159/000055265. Oncology. 1999. PMID: 10436413 Review.

8

Phase I study of oxaliplatin in patients with advanced cancer.

Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Extra JM, et al. Among authors: marty m. Cancer Chemother Pharmacol. 1990;25(4):299-303. doi: 10.1007/BF00684890. Cancer Chemother Pharmacol. 1990. PMID: 2295116

9

Prospects with docetaxel in the treatment of patients with breast cancer.

Marty M, Extra JM, Cottu PH, Espié M. Marty M, et al. Eur J Cancer. 1997 Aug;33 Suppl 7:S26-9. doi: 10.1016/s0959-8049(97)90007-1. Eur J Cancer. 1997. PMID: 9486101 Review.

10

High-dose epirubicin and cyclophosphamide every two weeks as first-line chemotherapy for relapsing metastatic breast cancer patients.

Cottu PH, Zelek L, Extra JM, Espie M, Mignot L, Morvan F, Marty M. Cottu PH, et al. Among authors: marty m. Ann Oncol. 1999 Jul;10(7):795-801. doi: 10.1023/a:1008353904351. Ann Oncol. 1999. PMID: 10470426 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

795 results

Search Page

Filters